Abstract 14752: Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial

Christopher P. Cannon,Vlado Perkovic,Rajiv Agarwal,James Baldassarre,George L. Bakris,Barry M. Brenner,David M. Charytan,Dick de Zeeuw,Robert M. Edwards,Tom Greene,Hiddo J.L. Heerspink,Meg Jardine,Adeera Levin,Jingwei Li,Bruce Neal,Carol A. Pollock,David C. Wheeler,Hong Zhang,Bernard Zinman,Kenneth W. Mahaffey

Abstract 14752: Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial

2019

Background: SGLT2 inhibitors have to date been recommended as add-on therapy for patients whose HbA1c is not at goal, typically >7%, based on the initial clinical trials. We sought to determine if ...

Keywords:

Kidney disease
Clinical trial
Diabetes type ii
Renal function
Type 2 diabetes
Canagliflozin
Internal medicine
Credence
Medicine
Cardiology
Diabetes mellitus
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations